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Summary
Because of its anabolic effects on muscle, testosterone is being
explored as a function-promoting anabolic therapy for functional
limitations associated with aging; however, concerns about
testosterone’s adverse effects on prostate have inspired efforts
to develop strategies that selectively increase muscle mass while
sparing the prostate. Testosterone’s promyogenic effects are
mediated through upregulation of follistatin. We show here that
the administration of recombinant follistatin (rFst) increased
muscle mass in mice, but had no effect on prostate mass.
Consistent with the results of rFst administration, follistatin
transgenic mice with constitutively elevated follistatin levels
displayed greater muscle mass than controls, but had similar
prostate weights. To elucidate signaling pathways regulated
differentially by testosterone and rFst in prostate and muscle, we
performed microarray analysis of mRNAs from prostate and
levator ani of castrated male mice treated with vehicle, testos-
terone, or rFst. Testosterone and rFst shared the regulation of
many transcripts in levator ani; however, in prostate, 593
transcripts in several growth-promoting pathways were differ-
entially expressed after testosterone treatment, while rFst
showed a negligible effect with only 9 transcripts differentially
expressed. Among pathways that were differentially responsive
to testosterone in prostate, we identified ornithine decarboxyl-
ase (Odc1), an enzyme in polyamine biosynthesis, as a testoster-
one-responsive gene that is unresponsive to rFst. Accordingly, we
administered testosterone with and without a-difluoromethylor-
nithine (DFMO), an Odc1 inhibitor, to castrated mice. DFMO
selectively blocked testosterone’s effects on prostate, but did not
affect testosterone’s anabolic effects on muscle. Co-administra-
tion of testosterone and Odc1 inhibitor presents a novel thera-
peutic strategy for prostate-sparing anabolic therapy.
Key words: aging; anti-aging; sarcopenia; sex hormones;
skeletal muscle; steroids.
Introduction
Testosterone’s anabolic effects on the skeletal muscle are widely
recognized (Bhasin et al., 2006). Testosterone levels in men are positively
associated with skeletal muscle mass, strength, and physical function
(Roy et al., 2002; Orwoll et al., 2006). Consistent with these epidemi-
ological correlations, testosterone administration also increases lean
body mass and maximal voluntary strength in men (Bhasin et al., 1996;
Bhasin et al., 1997; Snyder et al., 1999; Wang et al., 2000; Page et al.,
2005; Srinivas-Shankar et al., 2010). A number of androgens, including
testosterone, are being investigated as function-promoting anabolic
therapies for the treatment of functional limitations associated with
aging and chronic illness (Bhasin et al., 2006). However, concerns about
the potential prostatic side effects of testosterone have limited enthu-
siasm for testosterone’s applications as a function-promoting anabolic
therapy in older men (Bhasin et al., 2006; Calof et al., 2005). Thus, there
is an unmet need for novel therapeutics that selectively exert anabolic
effects on the muscle, but which are free of adverse effects on prostate
(Bhasin et al., 2006; Dalton et al., 2011; Basaria et al., 2013). Here, we
report a novel strategy for achieving the selectivity of testosterone’s
anabolic actions on skeletal muscle while sparing the prostate.
We have reported that testosterone promotes myogenic differenti-
ation of muscle progenitor cells by activating AR/b-catenin pathway and
inducing the expression of a number of Wnt-target genes, including
follistatin (Singh et al., 2009; Braga et al., 2012). Follistatin is essential
for mediating testosterone’s effects on myogenesis; blocking follistatin’s
action using either antifollistatin antibodies or siRNAs blocks testoster-
one’s effects on myogenic differentiation of muscle progenitor cells
(Singh et al., 2009; Braga et al., 2012). These data suggested that
testosterone and follistatin likely activate analogous pathways in the
muscle. We show here that the administration of recombinant follistatin
(rFst) increased muscle mass, as expected (Lee, 2007; Kota et al., 2009;
Singh et al., 2009; Dalton et al., 2011; Braga et al., 2012), but
surprisingly, unlike testosterone, rFst did not affect prostate mass. These
data suggested that in prostate, testosterone activates signaling path-
ways that contribute to prostate growth, but which are not activated by
follistatin.
To identify signaling pathways in the prostate that are activated
selectively by testosterone, we performed microarray analysis of mRNAs
in prostate and levator ani of castrated mice treated with placebo,
testosterone, or rFst. Among biological processes that were differentially
activated in prostate by testosterone, but not by follistatin, we identified
Correspondence
Shalender Bhasin and Ravi Jasuja, Research Program in Men’s Health: Aging and
Metabolism, Boston Claude D. Pepper Older Americans Independence Center,
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115,
USA. Tel.: +1 617 525 9043; fax: +1 617 732 5764; e-mails: sbhasin@partners.org;
rjasuja@partners.org
Accepted for publication 21 October 2013
ª 2013 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
303
Aging Cell (2014) 13, pp303–310 Doi: 10.1111/acel.12174
Ag
in
g 
Ce
ll
polyamine biosynthesis as a key androgen-sensitive pathway that is
known to regulate prostate growth (Pegg & Williams-Ashman, 1968;
Danzin et al., 1982). Ornithine decarboxylase (Odc1), the rate-limiting
enzyme in polyamine biosynthesis, was differentially expressed in the
prostate glands of testosterone-treated mice, while showing no signif-
icant change in rFst-treated mice. We reasoned that if Odc1 is essential
for mediating testosterone’s effects on the prostate, but not the muscle,
then the administration of testosterone plus Odc1 inhibitor should block
testosterone’s effects on prostate mass, but not on muscle mass. Indeed,
we show here that combined administration of testosterone plus
a-difluoromethylornithine (DFMO), an irreversible Odc1 inhibitor,
increased muscle mass, but did not induce prostatic growth. Thus,
combination of testosterone plus an Odc1 inhibitor provides a novel
therapeutic approach for achieving the selectivity of testosterone’s
effects on the muscle while sparing the prostate.
Results
rFst increases lean mass and decreases fat mass without
affecting prostate growth
Previous studies have shown that the effects of testosterone on
differentiation of mesenchymal progenitor cells are mediated through
follistatin (Singh et al., 2009; Braga et al., 2012). These observations
suggested that follistatin might exert effects on androgen-responsive
tissues, such as the muscle, fat, and prostate, similar to those of
testosterone. Indeed, follistatin has been shown to increase skeletal
muscle mass (Lee, 2007; Kota et al., 2009); however, the data on its
effects on the prostate and adipose tissue have been discordant
(McPherson et al., 1997; Hirai et al., 2007; Flanagan et al., 2009;
Tumminello et al., 2010; Nakatani et al., 2011). Higher circulating
follistatin levels have been correlated with increased fat mass (Flanagan
et al., 2009); follistatin has also been reported to induce adipogenic
differentiation of preadipocytes (Hirai et al., 2007). However, transgenic
expression of a follistatin peptide in mice was associated with reduced fat
accumulation (Tumminello et al., 2010). Follistatin neutralizes activin-
mediated suppression of prostate cell growth (McPherson et al., 1997);
furthermore, follistatin levels in men with prostate cancer have been
associated with increased risk of bone metastasis (Nakatani et al., 2011).
To determine the effects of follistatin on androgen-responsive tissues
– muscle, fat, and the prostate, we expressed rFst protein and
administered graded doses of rFst to C57BL6 adult male mice (Fig. 1).
rFst administration was associated with dose-dependent increases in
circulating follistatin levels and lean body mass, measured using nuclear
magnetic resonance (Fig. 1A). The wet weights of levator ani, gastroc-
nemius, and quadriceps femoris muscle groups were related to rFst dose
(Fig. 1B) and were significantly higher in mice treated with 100 lg rFst
daily than in vehicle-treated mice. rFst administration was associated
with a dose-dependent reduction in whole-body and intra-abdominal fat
mass (Fig. 1A,C).
Surprisingly, rFst administration did not significantly affect prostate
weight (Fig. 1D). Even in mice receiving the highest dose of rFst (100 lg
daily), the mean prostate weight was not significantly different from that
in vehicle-treated mice, while the levator ani weight was 25% higher
than in vehicle-treated controls.
To further characterize the effect of rFst on the growth of prostate
cells, we incubated androgen-responsive primary prostate epithelial cells
with 0, 5, or 25 ng mL1 rFst or with methyltrienolone (R1881), a
synthetic nonaromatizable androgen (Fig. 1E). As expected, R1881
upregulated the mRNA levels of cell growth marker PCNA, but rFst had
no effect on PCNA expression even at concentrations that were nearly
100-fold higher than those in human circulation (O’Connor et al.,
1998).
Additionally, we examined the effects of rFST and an androgen,
R1881, on the proportion of androgen-sensitive LNCaP cells in S phase in
cell cycle analysis using BrdU incorporation combined with DNA
intercalation dye 7-AAD. The cell cycle phases of actively dividing LNCaP
cells (BrdU+) were resolved using fluorescence-activated cell sorting.
Unlike R1881, which increased BrdU incorporation as well as the fraction
of LNCaP cells in S phase at concentrations as low as 0.1 nM, rFst had no
significant effect on either the percent of BrdU+ cells or the fraction of
cells in S phase (Fig. 1F).
Differential effects of follistatin hyperexpression on skeletal
muscle mass and prostate in follistatin transgenic mice
Follistatin transgenic mice, in which higher circulating levels of follistatin
are derived from its constitutive overexpression in skeletal muscle (Lee,
2007), had higher lean mass than their wild-type littermates (Fig. 2A).
The wet weights of levator ani, gastrocnemius, and quadriceps were also
significantly higher in follistatin transgenic mice than in wild-type
controls (Fig. 2B), even after adjusting for body weights. However,
prostate weights did not differ significantly between the follistatin
transgenic and wild-type mice (Fig. 2C). These data further support the
notion that follistatin selectively promotes muscle growth, but spares the
prostate.
Microarray analysis of genes and pathways differentially
regulated by testosterone and rFst in the muscle and prostate
As follistatin is in the signaling pathway that mediates the effects of
testosterone on myogenesis, the observations that rFst selectively
increased skeletal muscle mass, but did not affect prostate growth or
the markers of prostate cell proliferation in vitro, suggested that
testosterone differentially activates specific signaling pathways in the
prostate that are not activated by rFst. We surmised that signaling
pathways that are activated in prostate by testosterone, but not by rFst,
are the likely mediators of testosterone’s effects on the prostate and
would be of interest with respect to developing therapeutic strategies for
achieving the selectivity of testosterone’s actions.
Accordingly, we used microarray analysis to characterize the tran-
scriptome of levator ani and prostate under the following conditions: (i)
intact male mice, (ii) castrated male mice treated with vehicle alone, (iii)
castrated male mice treated with testosterone, and (iv) castrated male
mice treated with rFst. A minimum of four replicates were run for each
group. A gene was considered androgen sensitive if it was differentially
expressed at a q-value < 0.2 comparing intact to castrated mice and
castrated mice to testosterone-treated castrated mice. Similarly, a gene
was considered follistatin sensitive if it was differentially expressed at a
q-value < 0.2 comparing intact to castrated mice and castrated mice to
follistatin-treated castrated mice. After compiling the lists of genes
classified as androgen sensitive and follistatin sensitive, Gene Ontology
(GO) term enrichment analysis was performed to identify GO terms over-
represented in either category (Table S1).
There were 852 genes classified as androgen sensitive and 778
classified as follistatin sensitive in the levator ani (Fig. 3A,B). Of these
genes, 391 were found to be both androgen and follistatin sensitive. As
expected from the anabolic effects of both testosterone and follistatin
on skeletal muscle, GO term enrichment revealed a large number of
biological processes related to cell growth and development (Fig. 3B).
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Microarray analysis of prostate yielded results that were strikingly
different from those in the muscle (Fig. 3A–C). We identified 593
androgen-sensitive genes, but only 9 follistatin-sensitive genes. Of the
nine follistatin-sensitive genes, seven were also androgen sensitive.
These microarray analyses are consistent with the observations that
testosterone promotes the growth of both muscle and prostate, while
rFst only affects muscle growth, but spares the prostate.
The microarray data provide a basis from which we can identify
biological processes that can be targeted to reduce the androgenic
effects of testosterone on the prostate. Among the biological pathways
that were activated in the prostate selectively by testosterone (Fig. 3B;
Fig. S1), we identified polyamine biosynthetic pathway as a key target
for several reasons. First, polyamine synthesis was androgen sensitive,
but not follistatin sensitive, in the prostate; this pathway was not among
those differentially induced by testosterone and rFst in levator ani.
Second, polyamine biosynthesis is known to be important in the
regulation of prostate growth (Pegg & Williams-Ashman, 1968; Danzin
et al., 1982). Third, ornithine decarboxylase (Odc1), a key enzyme in
polyamine biosynthesis, exhibited an expression signature indicative of
its differential regulation by testosterone in the prostate (Fig. 3C,
R2 R2 R2 
R2 R3 R3R3 R3 
R4 R4 
R4 R4 
7-AAD 7-AAD 7-AAD7-AAD
An
ti-
Br
dU
 F
IT
C
Co
ntr
ol
5 n
g/m
L F
st
25
 ng
/m
L F
st
1 n
M R
18
81
0
2
4
6
8
10
12 **
PC
N
A
/S
18
m
R
N
A
 e
xp
re
si
on
Control 0.1 n R1881
5 ng/mL rFst 25 ng/mL rFst 
Co
ntr
ol
0.1
 nM
 R
18
81
5 n
g/m
L r
Fs
t
25
 ng
/m
L r
Fs
t
0
10
20
30
Control rFST 100 ug/day
 *
%
 B
rd
U
+i
ve
 c
el
ls
(A) (C)
(B)
(D)
(F)
(E)
Fig. 1 Recombinant follistatin (rFst) increases lean mass and decreases fat mass without affecting prostate growth. (A) rFst supplementation dose dependently increases
circulating follistatin levels. Changes in percent lean body mass (middle panel) and fat mass (right panel) were related to rFst dose (P < 0.0001). Data are mean  SEM,
n = 6 in each group. (B) Mean  SEM wet weights of levator ani, gastrocnemius, and quadriceps femoris were significantly higher in mice treated with 100 lg rFst
daily than in vehicle-treated mice. n = 6 in each group. (C) Marked hypertrophy of lower extremity muscles and a reduction in intra-abdominal fat mass in 8-week-old male
mice treated with vehicle (rFst 0) or 100 lg of rFst (rFst 100) daily for 13 weeks. (D) Mean  SEM prostate weights in mice treated with 0, 10, 30, and 100 lg rFst daily for
13 weeks. Prostate weights did not differ between animals treated with rFst or vehicle. (E) rFst does not affect PCNA expression in primary prostate epithelial cells.
Primary prostate epithelial cells, synchronized for 24 h, were incubated with 0, 5, or 25 ng mL1 rFst or 1 nM R1881, an androgen. PCNA mRNA expression, measured
using quantitative PCR and normalized against 18S ribosomes, was upregulated nearly 10-fold by R1881, but was unaffected by rFst even at concentrations that were nearly
100 times the circulating follistatin levels in humans. (F) rFst supplementation does not affect BrdU incorporation or the fraction of LnCaP cells in the S phase. The
panels show the flow cytometric profile; R2, R3, and R4 represent the fraction of cells in G1, S, and G2/M phases, respectively. While R1881 even at concentrations as low as
0.1 nM increased the percent of cells in the S phase and the percent of BrdU+ cells, neither 5 nor 25 ng mL1 rFst had any significant effect on the percent of BrdU+ cells.
*P < 0.05; **P < 0.01 vs. control.
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Fig. 2 Differential effects of follistatin hyperexpression on skeletal muscle mass and prostate in follistatin transgenic mice. (A) Follistatin transgenic mice (Fst Tg) had
significantly higher lean body mass than wild-type controls. (B) Follistatin transgenic mice had higher weights of levator ani, gastrocnemius, and quadriceps femoris than
wild-type controls. (C) Prostate weights did not differ significantly between follistatin transgenic mice and wild-type controls. **P < 0.05 vs. wild-type controls.
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Fig. S2). Selective upregulation of Odc1 by testosterone, but not by rFST,
was confirmed in LNCaP cells treated with 100 nM testosterone or
125 ng mL1 rFst over a period of 24 h (Fig. S3). A time-course
evaluation of testosterone supplementation to castrated mice exhibited
time-dependent upregulation of Odc1; there was a close concordance
between prostate weight recovery and the increase in Odc1 expression
in response to testosterone administration (Figs S4 and S5).
Odc1 was significantly downregulated upon castration in the pros-
tate, and its expression was restored after testosterone administration,
but not after rFst administration. In the levator ani, Odc1 expression
showed little or no difference in its expression levels under any treatment
(Fig. 3C). Finally, Odc1 catalyzes the decarboxylation of L-ornithine to
form putrescine, which is known to be important in the regulation of
prostate growth (Pegg & Williams-Ashman, 1968; Danzin et al., 1982;
Pegg, 1988). Our data combined with the previous characterization of
Odc1 as a molecule that is important in prostate growth and is androgen
sensitive led us to hypothesize that Odc1 may be the basis of the
differential sensitivity of the prostate to testosterone and rFst.
Inhibition of Odc1 by DFMO blocks testosterone’s effects on
the prostate while retaining its anabolic effects on the muscle
We reasoned that if Odc1 were essential for mediating testosterone’s
effects on the prostate, but not the muscle, then the inhibition of Odc1
activitywould be expected to attenuate the prostate-stimulating effects of
testosterone while retaining its anabolic effects on the muscle. Accord-
ingly, adult male intact and castrated mice were treated for 2 weeks
with vehicle or testosterone with and without DFMO, a specific Odc1
inhibitor, as follows: intact (I), castrated (Cx), castrated + 15 lg per day
testosterone (Cx + T), and castrated +15 lg per day testoster-
one + 15 lg per day DFMO (Cx + T + DFMO). The doses and duration
of DFMO treatment were based on previous studies that demonstrated
effective inhibition of ODC activity in vivo (Danzin et al., 1982).
As expected, castrated mice had significantly lower levator ani weight
as well as lower prostate weight than intact controls (Fig. 4A,B).
Testosterone administration alone in castrated mice restored the weights
of prostate and levator ani muscle to those observed in intact eugonadal
controls. Importantly, combined administration of testosterone plus
DFMO restored levator ani mass to that of intact controls and
testosterone-treated castrated mice. However, prostate weights in
castrated mice treated with testosterone plus DFMO were significantly
lower than those of intact controls. Furthermore, testosterone admin-
istration prevented the involution of prostate gland and lumen observed
in castrated mice; co-administration of DFMO blocked the testosterone’s
effect on prostate epithelial growth (Fig. 4C). Thus, Odc1 is essential for
mediating testosterone’s effects on the prostate, but not muscle.
Discussion
The past decade has witnessed enormous pharmaceutical interest in the
development of selective androgen receptor modulators (SARMs) that
have preferential anabolic effects on the muscle, but which are relatively
selective with respect to the prostate (Bhasin et al., 2006; Dalton et al.,
2011; Basaria et al., 2013). We report here two novel therapeutic
strategies for achieving the selectivity of anabolic effects on the skeletal
muscle while sparing the prostate. We show that Odc1, a rate-limiting
enzyme in the polyamine biosynthetic pathway, is an important mediator
of testosterone’s effects on the prostate and that the administration of
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testosterone in combination with an Odc1 inhibitor blocks testosterone’s
effects on the prostate, but not on the muscle. Additionally, we show
here that follistatin, a mediator of testosterone’s effects on myogenesis,
selectively increases skeletal muscle mass without affecting the prostate.
Although both strategies could potentially exert anabolic effects while
sparing the prostate, the testosterone plus Odc1 inhibitor combination
could be attractive in patient populations in whom improvements in
sexual function may be a desired outcome. Furthermore, testosterone
and DFMO have been administered previously to humans and approved
by FDA for other indications; therefore, they provide an accelerated path
to clinical application.
Ornithine decarboxylase is a widely distributed enzyme that is
expressed in the prostate as well as in the skeletal muscle (Pegg &
Williams-Ashman, 1968; Pegg, 1988; J€anne et al., 1991; Lee et al.,
2011). Polyamine synthesis has been implicated in the regulation of
prostate growth (Pegg, 1988; J€anne et al., 1991). The enzyme, ornithine
decarboxylase, the first enzyme in the polyamine synthesis that converts
ornithine to putrescine, has been shown to interact directly with
androgen receptor, contains an AR-binding site in its promoter, and
plays an important role in the regulation of prostate growth (Pegg &
Williams-Ashman, 1968; Danzin et al., 1982). The polyamines are
essential for proliferating cells (Pegg, 1988), especially in the prostate.
Testosterone has been reported to regulate ornithine decarboxylase in
the muscle and prostate (J€anne et al., 1991). Our data demonstrate that
Odc1 is essential for mediating testosterone’s effects on the prostate,
but not on the muscle. These observations suggest that the combination
of testosterone plus DFMO or other Odc1 inhibitors can serve as selective
androgen therapy that spares the prostate. Odc1 is an attractive
therapeutic target due to its short half-life and because a number of
Odc1 inhibitors have been developed previously for other indications
(Abeloff et al., 1984; Boitz et al., 2009). Separately, testosterone and
DFMO each have been administered previously to humans for other
indications. Testosterone alone has been used for the treatment of
hypogonadism in men, while DFMO alone has been used for the
treatment of leishmaniasis, hirsutism, and other disorders (Abeloff et al.,
1984; Bhasin et al., 2006; Boitz et al., 2009). Preclinical and clinical data
on their safety when they are administered alone are available. Thus, the
combination of testosterone plus DFMO combination could proceed to
clinical trials with more limited preclinical toxicology studies than are
typically required for completely new molecules.
While we have focused on the Odc1 pathway because of its known
role in prostate growth, it is possible that additional pathways may play
an important direct or indirect role in mediating testosterone’s effects on
the prostate. In addition to the prostate and muscle, testosterone
regulates other physiological processes, including erythropoiesis, bone
health, secondary sex characteristics, and sexual function. While we have
shown that the Odc1 inhibitor, DFMO, blocks the prostate effects of
testosterone without attenuating its anabolic effects on the muscle,
additional studies are needed to ensure that other physiological effects
of testosterone, especially on sexual function and bone, are not
attenuated by the administration of an Odc1 inhibitor.
This drug combination would be particularly attractive for the
treatment of conditions in which testosterone therapy alone may be
associated with a high risk of adverse prostate events, such as older men
with low testosterone levels, hypogonadal men at increased risk of
prostate cancer, or men with prostate cancer who have undergone
radical prostatectomy and are at low risk of disease recurrence.
Accordingly, the therapeutic applications of the combination of testos-
terone plus DFMO or other Odc1 inhibitors as selective androgen/
anabolic therapy that spares the prostate should be explored.
Methods
Expression and purification of human Fst288 (rFst)
Follistatin 288 (Fst288, amino acid residues 30–317) cDNA was cloned
into Sal1/Xho1 site of pET30 and expressed with His-tag in E. coli BL21
(DE3) after induction with IPTG. Cell lysate was centrifuged and the
pellet was solubilized in a buffer containing 50 mM Tris–HCl, 8 M urea,
100 mM PMSF, pH 8.0. His-tagged Fst288 was purified with HisPur
cobalt spin column (Thermo scientific, Rockford, IL, USA). Purified
protein in elution buffer containing 8 M urea was diluted 1:4 with
200 mM Tris–HCl, pH 10, and 2 mM DTT and dialyzed against Tris buffer
(10 mM Tris–HCl, 1 mM NaCl, pH 8.0) at 4°C. Purified protein was passed
through Endotoxin Removal Gel and stored at 80°C in 20% glycerol.
Biological activity of Fst288 was verified by its ability to neutralize the
growth inhibitory effect of activin on mouse MPC11 cells (Phillips et al.,
1999). About 106 viable cells were incubated in 0.1 mL DMEM
supplemented with 10% fetal calf serum, penicillin and streptomycin,
and 25 lM b-mercaptoethanol in a 96-well plate. Activin (Stemgent,
MA, USA) was added and cells were allowed to grow for 48 h before the
addition of 0.25 lCi of [3H] thymidine (6.7 Ci mmol1) for another
24 h. Thymidine incorporation in cells was measured by Cerenkov
counter.
rFst administration
Eight-week-old C57BL6 mice (Jackson Laboratory, Bar Harbor, ME, USA)
were housed in Laboratory Animal Science Center, using the protocols
approved by the Institutional Animal Care and Use Committee of Boston
University.
Animals were allowed to recover for 1 week before random
assignment to one of four groups (n = 6 in each group) to receive 0,
10, 30, or 100 lg rFst in phosphate-buffered saline containing 20%
glycerol by daily subcutaneous injection for 13 weeks. Body weights and
lean and fat mass were measured weekly using EchoMRI-700 (Echo
Medical System, Houston, TX, USA). Wet weights of muscle groups and
dorsal prostate were measured after euthanasia.
Microarray transcriptome analysis
Ten-week-old male mice were randomized to one of four groups: sham
(control) operated, vehicle treated (n = 4), castrated, vehicle treated
(n = 4), castrated+ testosterone treated (15 lg daily; n = 4), and
castrated + rFst treated (15 lg daily; n = 4). Mice underwent castration
under ketamine–xylazine, allowed to recover for 2 weeks, and injected
subcutaneously with vehicle, 15 lg testosterone, or 15 lg rFst. The mice
were euthanized after 24 h, and prostate and levator ani muscle were
harvested.
Total RNA was prepared, and biotin-labeled cDNA was hybridized to
Affymetrix Mouse 430 2.0 chips. Raw data were background-corrected,
quantile-normalized, and summarized into log-transformed expression
values using median polish according to RMA methodology (Irizarry
et al., 2003).
Differential expression calculations were made using linear models to
calculate a moderated t-statistic as detailed in Smyth (2004). A
Benjamini–Hochberg correction was used to account for multiple
hypothesis testing. All statistical calculations were made using
limma package in R statistical program (http://bioconductor.org/pack-
ages/release/bioc/html/limma.html; http://www.rproject.org/;ftp://ftp.
informatics.jax.org/pub/reports/index.html#go). A gene was classified
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as ‘androgen sensitive’ if it showed differential expression at a
q-value < 0.2 under these two comparisons: (i) castrated versus sham-
treated mice and (ii) testosterone-treated versus castrated mice. A gene
was classified as ‘follistatin sensitive’ if it showed differential expression
at a q-value < 0.2 under these two comparisons: (i) castrated versus
sham-treated mice and (ii) rFst-treated versus castrated mice.
Gene Ontology term enrichment was used to identify biological
processes over-represented in sets of genes identified through gene
expression analysis. Gene annotations were limited to ‘biological process’
branch of the ontology and downloaded from the Mouse Genome
Informatics (MGI) database. GO is a hierarchy, gaining biological
specificity the further a term is away from the root. This parent–child
relationship implies that a gene annotated to a child term is also
annotated to the parent term, which in turn is annotated to all
descendent terms. Accordingly, gene annotations were mapped to the
GO and a gene was subsumed by all parent terms. This results in the root
term, biological process, being annotated to all genes. The revised gene
to GO termmapping was then filtered to remove GO terms with very high
frequency and very low frequency. We required a term to have <300 and
>5 associated genes for further analysis. For a set of genes, GO term
enrichment for term i was calculated using hypergeometric function,
Fiðx; k;m; nÞ ¼
m
x
 
n
k  x
 
mþ n
k
  ;
where m is the number of genes that term i is annotated to cover the
entire dataset, n is the number of genes that are annotated with any GO
term over the entire dataset, k is the number of genes that are selected,
and x is the number of times term i is selected from k genes.
Time-course experiments of testosterone administration in
castrate mice
Eight-week-old C57BL6 mice (Jackson Laboratory) were housed in
Laboratory Animal Science Center, using the protocols approved by the
Institutional Animal Care and Use Committee of Brigham and Women’s
Hospital. Animals were allowed to recover for 1 week before random
assignment to one of three groups (n = 6 in each group): intact,
castrated, or castrated + T to receive oil, oil, and oil + 30 lg T
subcutaneously, respectively. The animals were euthanized at days 1,
3, 7, and 14 after the start of treatment. Wet weights of dorsal prostate
were measured after euthanasia, and Odc1 expression was followed by
qPCR analysis.
In vitro studies
LNCaP cells, obtained from the American Type Culture Collection
(Rockville, MD, USA), were maintained in 100-mm dishes (Corning, NY,
USA) in RPMI 1640 supplemented with 5% fetal bovine serum and 1%
antimycotic–antibioticmix (Life Technologies, Rockville,MD, USA) at 37°C
in 5% CO2. Cell cycle analysis was performed using FITC BrdU kit (BD
Pharmingen, San Diego, CA, USA) according to the established protocols.
Cells we pulsed with BrdU for 30 min, washed in phosphate-buffered
saline containing 5% FBS, fixed and permeabilized with cytofix, and
washed with Perm/Wash buffer. Subsequently, cells were treated with
30 mg of DNase for 1 h and stained with FITC-conjugated anti-BrdU
antibody and 7-aminoactinomycin D (7-AAD) before flow cytometric
analysis. DNA content was analyzed using a FACSscan flow cytometer.
Primary prostate epithelial cells, obtained from Clonetics, were main-
tained in growthmedium and synchronized for 24 h before the treatment
with testosterone or rFst. PCNA mRNA expression was measured using
quantitative PCR and normalized against the density of 18S ribosomes.
For the time-course experiments, LnCap cells were allowed to seed on
T-25 flasks at 80% confluency overnight. Next day, cells were treated
with vehicle (Con), 100 nM testosterone (Test), or 125 ng mL1 rFst for
different time points (0–24 h). Western blotting was performed
according to the standard protocols. Typically, 40 lg total cell lysates
was run on 4–15% SDS-PAGE (BioRad, Herculus, CA, USA), electro-
transferred to PVDF membranes, and probed with Odc1 (1:500 dilutions,
Hybridoma Bank) or a-tubulin (1:5000 dilutions, Chemicon) primary
antibodies overnight. Membranes were incubated with HRP-conjugated
mouse secondary antibody (1:1000) for 1 h at room temperature and
developed using ECL reagent (Amersham, CA, USA). Densitometric
scanning was performed to deduce relative Odc1 protein expression
after normalization with a-tubulin.
Testosterone and DFMO administration
Stock solutions of testosterone propionate (T) in sesame oil and DFMO in
saline solution were stored at 4°C. The mice were divided into following
groups: intact, castrate (CX), castrate co-administered with T and DFMO
(Cx + T + DFMO), and castrate administered with testosterone (Cx + T).
Each mouse received a subcutaneous injection of either 15 lg TP in
100 lL sesame oil or 100 lL sesame oil alone. This was followed by an
intraperitoneal injection of 7.5 mg DFMO in 100 lL saline solution for
Cx + T + DFMO group, or an intraperitoneal 100 lL saline injection for
all other groups. Each afternoon, the DFMO or saline injection was
repeated for all mice. Animals were euthanized on the 14th day and
tissues were weighed.
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